Evidence‑Based Guidelines for Venous Stenting in Chronic Venous Outflow Obstruction

Clinical Indications

Post‑thrombotic syndrome with documented iliac vein obstruction that impairs quality of life – the Circulation guideline recommends stenting when symptoms persist despite optimal medical therapy. 3
Persistent venous ulcers with duplex ultrasound evidence of iliocaval obstruction – the American College of Radiology advises consideration of endovascular reconstruction in this setting. 4
Rapid extension of thrombus despite therapeutic anticoagulation – the Circulation guideline classifies this as an urgent indication for immediate thrombus removal and subsequent stenting. 3
Worsening symptoms while on anticoagulation alone – the Circulation guideline cites this as a trigger for endovascular intervention. 3

Duplex ultrasound is the mandatory first‑line screening tool for detecting non‑phasic common femoral vein waveforms, reduced flow augmentation, and diffuse reflux. (American College of Radiology) 4
CT or MR venography of the abdomen/pelvis is required before intervention to delineate stenosis location, collaterals, and anatomic variants; unrecognized variants account for 15–35 % of 2‑year recurrences. (American College of Radiology) 6
Intravascular ultrasound (IVUS) performed at the time of catheter venography is the most sensitive modality for deep‑vein obstruction; approximately 10 % of stenoses become apparent only after a trial balloon angioplasty. (American College of Radiology) 5

Angioplasty alone is insufficient; stent placement is required to achieve durable patency after lesion preparation. (Circulation) 3
Stent recanalization without prior thrombolysis yields 83–98 % anatomic success in chronic obstruction. (Circulation) 3
Stents should be confined to the iliac vein whenever feasible to maximize long‑term patency. (Circulation) 3
If the lesion extends into the common femoral vein, a caudal stent extension is acceptable, but expect modestly lower patency (≈90 % vs 84 %). (Circulation) 3
For isolated common femoral vein stenosis, attempt percutaneous transluminal angioplasty (PTA) without stenting first; stenting is reserved for refractory lesions. (Circulation) 3

Therapeutic anticoagulation should be continued with the same regimen used for iliofemoral DVT patients without stents to maintain patency. (Circulation) 3
Add antiplatelet therapy for patients at high risk of re‑thrombosis after individualized bleeding‑risk assessment (e.g., poor inflow vein quality, suboptimal anatomic result). (Circulation) 3

Initial symptom relief occurs in ~95 % of patients, with marked reduction in pain and swelling. (Circulation) 3
At three years, 79 % maintain pain improvement and 66 % maintain swelling reduction after successful stenting. (Circulation) 3
Venous ulcer healing is achieved in approximately 56 % of affected limbs following restoration of outflow. (Circulation) 3
Health‑related quality‑of‑life scores improve significantly and remain durable over long‑term follow‑up. (Circulation) 3

Stent fracture is rare (~1 % of cases) and can be managed by implanting a second stent, which restores patency without additional morbidity. (Circulation) 3
In pregnancy, previously placed iliac vein stents may deform late in gestation but typically resolve postpartum; prophylactic low‑molecular‑weight heparin prevented recurrent VTE in a series of 62 women. (Circulation) 3

High‑bleeding‑risk patients should not receive catheter‑directed thrombolysis or pharmacomechanical thrombectomy. (Circulation) 3
Chronic DVT symptoms >21 days are unsuitable for thrombolysis alone; stenting is required for durable results. (Circulation) 3
Systemic fibrinolysis is not recommended routinely for iliofemoral DVT due to unfavorable risk‑benefit profile. (Circulation) 3